Clinical Trial Update: A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. [Phase 2, Phase 3]

View source ↗

Summary

A registry entry for a first-line treatment study of Esophageal Squamous Cell Carcinoma using SYS6010, Enlonstobart, and chemotherapy, spanning Phase 2 and Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Chemotherapy (chemotherapy)
• Enlonstobart
• SYS6010

Snippet

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING